Defunct Company
Total Trials
8
As Lead Sponsor
0
As Collaborator
Total Enrollment
1,121
NCT02009449
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
Phase: Phase 1
Role: Collaborator
Start: Nov 15, 2013
Completion: Jul 22, 2023
NCT02923921
Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer
Phase: Phase 3
Start: Mar 1, 2017
Completion: Mar 5, 2020
NCT03267732
A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)
Start: Sep 5, 2017
Completion: Oct 30, 2017
NCT03381547
A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)
Start: Dec 18, 2017
Completion: Feb 11, 2018
NCT04194892
A Crossover Study to Evaluate Pegilodecakin (LY3500518) in Healthy Participants
Start: Jan 19, 2018
Completion: Mar 14, 2018
NCT03382899
Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer
Phase: Phase 2
Start: Mar 19, 2018
NCT03382912
Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer
Start: Mar 22, 2018
Completion: Mar 3, 2020